GLAUKOS CorpGKOSEarnings & Financial Report
Glaukos Corp is a medical technology company focused on ophthalmology, developing and commercializing minimally invasive surgical devices, prescription pharmaceuticals and consumer products for glaucoma, corneal diseases and other eye disorders. It operates primarily across North America, Europe and Asia Pacific, serving hospitals, ophthalmology clinics and patients worldwide.
GKOS Q1 FY2026 Key Financial Metrics
Revenue
$150.6M
Gross Profit
$117.2M
Operating Profit
$13.5M
Net Profit
$9.4M
Gross Margin
77.9%
Operating Margin
9.0%
Net Margin
6.2%
YoY Growth
41.2%
GLAUKOS Corp Q1 FY2026 Financial Summary
GLAUKOS Corp reported revenue of $150.6M (up 41.2% YoY) for Q1 FY2026, with a net profit of $9.4M (6.2% margin). Cost of goods sold was $33.3M, operating expenses totaled $103.7M.
Key Financial Metrics
| Total Revenue | $150.6M |
|---|---|
| Net Profit | $9.4M |
| Gross Margin | 77.9% |
| Operating Margin | 9.0% |
| Report Period | Q1 FY2026 |
GLAUKOS Corp Annual Revenue by Year
GLAUKOS Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $507.4M).
GLAUKOS Corp Quarterly Revenue & Net Profit History
GLAUKOS Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $150.6M | +41.2% | $9.4M | 6.2% |
| Q4 FY2025 | $143.1M | +35.7% | $-133.7M | -93.4% |
| Q3 FY2025 | $133.5M | +38.1% | $-16.2M | -12.2% |
| Q2 FY2025 | $124.1M | +29.7% | $-19.7M | -15.8% |
| Q1 FY2025 | $106.7M | +24.6% | $-18.1M | -17.0% |
| Q4 FY2024 | $105.5M | +28.1% | $-33.6M | -31.8% |
| Q3 FY2024 | $96.7M | +23.9% | $-21.4M | -22.1% |
| Q2 FY2024 | $95.7M | +19.0% | $-50.5M | -52.8% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $95.7M | $96.7M | $105.5M | $106.7M | $124.1M | $133.5M | $143.1M | $150.6M |
| YoY Growth | 19.0% | 23.9% | 28.1% | 24.6% | 29.7% | 38.1% | 35.7% | 41.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $919.7M | $926.5M | $974.8M | $966.2M | $987.0M | $999.4M | $893.5M | $893.3M |
| Liabilities | $254.5M | $258.0M | $207.8M | $202.2M | $221.8M | $229.8M | $237.3M | $222.4M |
| Equity | $665.2M | $668.5M | $766.9M | $764.0M | $765.1M | $769.5M | $656.2M | $670.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-18.4M | $-9.6M | $507000 | $-18.5M | $7.0M | $-10.1M | $6.8M |